Kinnate Biopharma (NASDAQ:KNTE) Downgraded by Zacks Investment Research to Sell

Kinnate Biopharma} stock has undergone multiple analysts rating changes in the recent past.  Kinnate Biopharma Downgraded by Zacks Investment Research on 10/19/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Kinnate Biopharma (NASDAQ:KNTE) Downgraded by Zacks Investment Research to Sell